Large-scale study provides real-world data on rare side effect of cancer immunotherapy
Researchers led by investigators at Mass General Brigham have published valuable information about a rare but serious complication of anti-cancer immunotherapy, providing the first large-scale description of its risk factors and clinical course, and underscoring the importance of early diagnosis and treatment. The findings are published in Blood and simultaneously presented at the American Society of Hematology Annual Meeting.
Source: Medical Xpress
Breast MRI may be safely omitted from diagnostic workup in certain patients with early-stage, HR-negative breast cancer
P a t i e n t s w i t h s t a g e 1 o r 2 , h o r m o n e r e c e p t o r ( H R ) - n e g a t i v e b r e a s t c a n c e r h a d s i m i l a r f i v e - y e a r r a t e s o f l o c o r e g i o n a l r e c u r r e n c e w h e t h e r o r n o t t h e y u n d e r w e n t p r e o p e r a t i v e b r e a s t m a g n e t i c r e s o n a n c e i m a g i n g ( M R I ) i n a d d i t i o n t o d i a g n o s t i c m a m m o g r a p h y t o d e t e r m i n e t h e e x t e n t o f t h e i r c a n c e r , a c c o r d i n g t o r e s u l t s f r o m t h e P h a s e I I I A l l i a n c e A 0 1 1 1 0 4 / A C R I N 6 6 9 4 c l i n i c a l t r i a l p r e s e n t e d a t t h e S a n A n t o n i o B r e a s t C a n c e r S y m p o s i u m ( S A B C S ) , h e l d D e c e m b e r 9 1 2 , 2 0 2 5 .
Source: Medical Xpress
Bladder cancer surgeons improve their performance when monitored and given feedback
The RESECT study, published in European Urology, is the first randomized controlled trial to examine whether feedback and education can enhance surgical performance for non-muscle-invasive bladder cancer (NMIBC), which has high rates of recurrence and progression.
Source: Medical Xpress
Combination immunotherapy for rare cancers shows improved efficacy and survival rates
New results from a multicenter clinical trial show that combining immunotherapy drugs nivolumab and ipilimumab significantly improves treatment response in patients with advanced and difficult-to-treat cancers. The trial results have been pre-published in JAMA Oncology, accompanied by a commentary emphasizing the significance of the findings.
